{"created":"2023-05-15T14:57:08.192177+00:00","id":77532,"links":{},"metadata":{"_buckets":{"deposit":"0d21095a-5f3d-49fa-9b88-144490047246"},"_deposit":{"created_by":1,"id":"77532","owners":[1],"pid":{"revision_id":0,"type":"depid","value":"77532"},"status":"published"},"_oai":{"id":"oai:repo.qst.go.jp:00077532","sets":["10:29"]},"author_link":["804575","804576","804581","804572","804573","804571","804574","804577","804579","804580","804583","804582","804578","804570"],"item_10005_date_7":{"attribute_name":"発表年月日","attribute_value_mlt":[{"subitem_date_issued_datetime":"2019-11-15","subitem_date_issued_type":"Issued"}]},"item_10005_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"Targeted α-particle therapy is a promising option for patients with malignant pheochromocytoma. Recent observations of α-emitting meta-[At-211]-astato-benzylguanidine ([At-211]-MABG) in a pheochromocytoma mouse model showed a strong anti-tumor effect [1], though the molecular mechanism remained elusive. Here, we show the comprehensive RNA-sequencing (RNA-seq) data for rat pheochromocytoma cell line PC12 cells based on in vitro [At-211]-MABG administration experiments. Enrichment analysis of differentially expressed genes (DEGs) and analysis of the gene expression profiles of cell cycle checkpoints revealed the mode of cell death via the p53-p21 signaling pathway after [At-211]-MABG treatment. Only p53-targeted genes were ranked among representative DEGs for decreased survival at all time points. Also, we estimated the low fluence rate of α-particles in in vitro [At-211]-MABG administration, approximately “one α-particle emission per one cell in one hour” for 10% survival. Long-lasting p53-induced signaling may break the wall of the “low fluence rate” in PC12 tumor cell death to exert anti-tumor effects. We recently published these findings on RNA-seq of in vitro PC12 transcriptome, suggesting that p53-p21 signaling pathway was an important cell death mechanism in anti-tumor effect of [At-211]-MABG [2].\n\nReferences: \n[1] Y. Ohshima et al., Eur J Nucl Med Mol Imaging, 2018. \n[2] Y. Ohshima et al., Theranostics, 2019","subitem_description_type":"Abstract"}]},"item_10005_description_6":{"attribute_name":"会議概要（会議名, 開催地, 会期, 主催者等）","attribute_value_mlt":[{"subitem_description":"日本放射線影響学会第62回大会","subitem_description_type":"Other"}]},"item_access_right":{"attribute_name":"アクセス権","attribute_value_mlt":[{"subitem_access_right":"metadata only access","subitem_access_right_uri":"http://purl.org/coar/access_right/c_14cb"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"坂下, 哲哉"}],"nameIdentifiers":[{"nameIdentifier":"804570","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"大島, 康宏"}],"nameIdentifiers":[{"nameIdentifier":"804571","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"河野, 暢明"}],"nameIdentifiers":[{"nameIdentifier":"804572","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"横田, 裕一郎"}],"nameIdentifiers":[{"nameIdentifier":"804573","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"渡辺, 茂樹"}],"nameIdentifiers":[{"nameIdentifier":"804574","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"佐々木, 一郎"}],"nameIdentifiers":[{"nameIdentifier":"804575","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"石岡, 典子"}],"nameIdentifiers":[{"nameIdentifier":"804576","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"荒川, 和晴"}],"nameIdentifiers":[{"nameIdentifier":"804577","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sakashita, Tetsuya","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"804578","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Oshima, Yasuhiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"804579","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Yokota, Yuuichiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"804580","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Watanabe, Shigeki","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"804581","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Sasaki, Ichiro","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"804582","nameIdentifierScheme":"WEKO"}]},{"creatorNames":[{"creatorName":"Ishioka, Noriko","creatorNameLang":"en"}],"nameIdentifiers":[{"nameIdentifier":"804583","nameIdentifierScheme":"WEKO"}]}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"conference object","resourceuri":"http://purl.org/coar/resource_type/c_c94f"}]},"item_title":"Anti-tumor effects of [At-211]-MABG treatment in PC12 pheochromocytoma cells and cell death via p53-p21 signaling pathway","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"Anti-tumor effects of [At-211]-MABG treatment in PC12 pheochromocytoma cells and cell death via p53-p21 signaling pathway"}]},"item_type_id":"10005","owner":"1","path":["29"],"pubdate":{"attribute_name":"公開日","attribute_value":"2019-09-10"},"publish_date":"2019-09-10","publish_status":"0","recid":"77532","relation_version_is_last":true,"title":["Anti-tumor effects of [At-211]-MABG treatment in PC12 pheochromocytoma cells and cell death via p53-p21 signaling pathway"],"weko_creator_id":"1","weko_shared_id":-1},"updated":"2023-05-15T23:41:15.431286+00:00"}